{
  "docId": "019de075-242a-7291-8f16-5f142d7cb798",
  "docSlug": "c8e6c54234adac3c3fb2311a09419808",
  "documentTitle": "Freeman Capital Management | Activist Presentation Deck | 15 slides",
  "authorId": "freeman-capital-management",
  "authorName": "Freeman Capital Management",
  "documentKindSlug": "activist-deck",
  "documentKindLabel": "Activist deck",
  "sourceTypeSlug": "activist_investor",
  "sourceTypeLabel": "Activist investor",
  "presentationDate": "2023-06-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 8,
  "pageCount": 15,
  "prevPage": 7,
  "nextPage": 9,
  "slideType": "peer_benchmark",
  "function": "compare_peers",
  "density": "balanced",
  "nDataPoints": 12,
  "notes": "The slide highlights MindMed's high compensation relative to poor stock performance.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de075-242a-7291-8f16-5f142d7cb798/8",
  "deckHref": "/decks/019de075-242a-7291-8f16-5f142d7cb798",
  "deckJsonHref": "/decks/019de075-242a-7291-8f16-5f142d7cb798.json",
  "deckAnchorHref": "/decks/019de075-242a-7291-8f16-5f142d7cb798#slide-8",
  "components": [
    {
      "bbox": {
        "h": 0.15,
        "w": 0.88,
        "x": 0.06,
        "y": 0.717
      },
      "kind": "callout",
      "text": "MindMed's Director Compensation Is Ranked #2 Even If You Substract the Special Bonuses for Vallone and Krebs",
      "attrs": null,
      "subkind": "primary",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "8c6b4de5-4810-4c24-9ef6-46d3447f56d9",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.02,
        "w": 0.15,
        "x": 0.047,
        "y": 0.95
      },
      "kind": "source-note",
      "text": "Source Refinitiv. See [20]",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "8d191d82-35db-4058-aa98-db8508b9eb5d",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.45,
        "w": 0.6,
        "x": 0.2,
        "y": 0.2
      },
      "kind": "table",
      "text": "Company, 2022 Average Non-Executive Director Compensation, 2022 Share Price Decline; Mind Medicine (MindMed) Inc., $688,191, -89%; Relmada Therapeutics Inc., $535,987, -84%; Compass Pathways Plc., $170,968, -64%; ATAI Life Sciences NV, $211,924, -67%; Numinus Wellness Inc., $150,198, -70%; Seelos Therapeutics Inc., $99,478, -56%",
      "attrs": null,
      "subkind": "data",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "8fbfc348-3407-443c-9ffd-96f78f382d7c",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.07,
        "w": 0.45,
        "x": 0.047,
        "y": 0.056
      },
      "kind": "title",
      "text": "Director Over-Compensation",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "6fac1b23-5849-479e-8d96-f52d27a56bf8",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 12,
      "from": 3,
      "beatId": "898b55c8-786a-402d-af69-12e8fbcb4368",
      "arcName": "Overcoming the Monster",
      "arcSlug": "overcoming-monster",
      "beatName": "The Monster (ISS and MindMed's flaws)",
      "beatSlug": "overcoming-monster-the-monster",
      "evidence": "Slides 3-12 expose contradictions and misleading statements by ISS and MindMed.",
      "position": 0,
      "confidence": 0.8,
      "parentBeatName": "Hook",
      "parentBeatSlug": "hook"
    }
  ],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}